Timothy DeVere Cook - 16 Sep 2022 Form 4 Insider Report for Athenex, Inc.

Role
Chief Business and Commercial Officer, Proprietary Drugs
Signature
/s/Steven Adams, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
16 Sep 2022
Net transactions value
-$224
Form type
4
Filing time
19 Sep 2022, 16:24:59 UTC
Previous filing
12 Sep 2022
Next filing
27 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNXQ Common Stock Options Exercise +2,250 +18% 14,465 16 Sep 2022 Direct F1
transaction ATNXQ Common Stock Tax liability $224 -548 -3.8% $0.4086* 13,917 16 Sep 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNXQ Restricted Stock Units Options Exercise $0 -2,250 -25% $0.000000 6,750 16 Sep 2022 Common Stock 2,250 Direct F1, F4
holding ATNXQ Stock Option (Right to Buy) 70,000 16 Sep 2022 Common Stock 70,000 $17.29 Direct
holding ATNXQ Stock Option (Right to Buy) 30,000 16 Sep 2022 Common Stock 30,000 $10.26 Direct F2
holding ATNXQ Stock Option (Right to Buy) 9,000 16 Sep 2022 Common Stock 9,000 $3.56 Direct F3
holding ATNXQ Stock Option (Right to Buy) 75,000 16 Sep 2022 Common Stock 75,000 $0.6655 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of stock.
F2 This option vests in four equal annual installments beginning on August 27, 2021.
F3 This option vests in four equal annual installments beginning on September 16, 2022.
F4 The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
F5 This option vests in four equal annual installments beginning on July 20, 2023.

Remarks:

Chief Business and Commercial Officer, Proprietary Drugs